Answers are grounded in this paper and cite their sources.
PURPOSE: To evaluate the effect of preoperative topical 0.1% nepafenac on intraoperative pain, pupil dynamics, and surgical outcomes in eyes with pseudoexfoliation syndrome (PEX) or mature cataract undergoing phacoemulsification. SETTING: Department of Ophthalmology, Çanakkale Onsekiz Mart University Hospital, Çanakkale, Türkiye. DESIGN: Prospective, non-randomized comparative clinical study. METHODS: Patients with PEX or mature cataract undergoing phacoemulsification received preoperative topical 0.1% nepafenac or no nepafenac. Pupil diameters were measured from surgical videos at surgery start (T1), after intracameral epinephrine (T2), after nucleus removal (T3), after cortex aspiration (T4), and after intraocular lens implantation (T5). Intraoperative pain, complications, and surgical outcomes were assessed. RESULTS: A total of 126 eyes were included: 32 PEX without nepafenac, 33 PEX with nepafenac, 31 mature cataract without nepafenac, and 30 mature cataract with nepafenac. Baseline characteristics were comparable among the groups (all P > .05). In PEX eyes, nepafenac did not significantly affect pupil diameter at any time point. In mature cataract eyes, pupil diameters were similar through T3 but significantly larger with nepafenac at T4 (7.30 ± 1.05 vs 6.38 ± 1.29 mm; P = .004) and T5 (6.85 ± 1.14 vs 5.87 ± 1.29 mm; P = .003). Pain scores, complication rates, and surgical outcomes were comparable between groups. CONCLUSIONS: Preoperative nepafenac improved maintenance of mydriasis during later surgical stages in mature cataract eyes but showed no significant benefit in PEX eyes. No significant effect on intraoperative pain or surgical outcomes was observed.
No takes yet. Share an insight, caveat, or question.
Alyoruk et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: